Levels	0	6	O
of	7	9	O
expression	10	20	O
of	21	23	O
CYR61	24	29	B-Gene_or_gene_product
and	30	33	O
CTGF	34	38	B-Gene_or_gene_product
are	39	42	O
prognostic	43	53	O
for	54	57	O
tumor	58	63	B-Pathological_formation
progression	64	75	O
and	76	79	O
survival	80	88	O
of	89	91	O
individuals	92	103	B-Organism
with	104	108	O
gliomas	109	116	B-Pathological_formation
.	116	117	O

The	119	122	O
biological	123	133	O
properties	134	144	O
of	145	147	O
CCN	148	151	B-Gene_or_gene_product
proteins	152	160	O
include	161	168	O
stimulation	169	180	O
of	181	183	O
cell	184	188	B-Cell
proliferation	189	202	O
,	202	203	O
migration	204	213	O
,	213	214	O
and	215	218	O
adhesion	219	227	O
,	227	228	O
as	229	231	O
well	232	236	O
as	237	239	O
angiogenesis	240	252	O
and	253	256	O
tumorigenesis	257	270	O
.	270	271	O

We	272	274	O
quantified	275	285	O
CYR61	286	291	B-Gene_or_gene_product
,	291	292	O
CTGF	293	297	B-Gene_or_gene_product
,	297	298	O
WISP	299	303	B-Gene_or_gene_product
-	303	304	I-Gene_or_gene_product
1	304	305	I-Gene_or_gene_product
,	305	306	O
and	307	310	O
NOV	311	314	B-Gene_or_gene_product
mRNA	315	319	O
expression	320	330	O
levels	331	337	O
in	338	340	O
samples	341	348	O
from	349	353	O
sixty	354	359	O
-	359	360	O
six	360	363	O
primary	364	371	O
gliomas	372	379	B-Pathological_formation
and	380	383	O
five	384	388	O
normal	389	395	O
brain	396	401	B-Multi-tissue_structure
samples	402	409	I-Multi-tissue_structure
using	410	415	O
quantitative	416	428	O
real	429	433	O
-	433	434	O
time	434	438	O
PCR	439	442	O
assay	443	448	O
.	448	449	O

Statistical	450	461	O
analysis	462	470	O
was	471	474	O
performed	475	484	O
to	485	487	O
explore	488	495	O
the	496	499	O
links	500	505	O
between	506	513	O
expression	514	524	O
of	525	527	O
the	528	531	O
CCN	532	535	B-Gene_or_gene_product
genes	536	541	O
and	542	545	O
clinical	546	554	O
and	555	558	O
pathological	559	571	O
parameters	572	582	O
.	582	583	O

Overexpression	584	598	O
of	599	601	O
CYR61	602	607	B-Gene_or_gene_product
,	607	608	O
CTGF	609	613	B-Gene_or_gene_product
,	613	614	O
WISP	615	619	B-Gene_or_gene_product
-	619	620	I-Gene_or_gene_product
1	620	621	I-Gene_or_gene_product
,	621	622	O
and	623	626	O
NOV	627	630	B-Gene_or_gene_product
occurred	631	639	O
in	640	642	O
48	643	645	O
%	645	646	O
(	647	648	O
32	648	650	O
of	651	653	O
66	654	656	O
)	656	657	O
,	657	658	O
58	659	661	O
%	661	662	O
(	663	664	O
38	664	666	O
of	667	669	O
66	670	672	O
)	672	673	O
,	673	674	O
36	675	677	O
%	677	678	O
(	679	680	O
24	680	682	O
of	683	685	O
66	686	688	O
)	688	689	O
,	689	690	O
and	691	694	O
15	695	697	O
%	697	698	O
(	699	700	O
10	700	702	O
of	703	705	O
66	706	708	O
)	708	709	O
of	710	712	O
primary	713	720	O
gliomas	721	728	B-Pathological_formation
,	728	729	O
respectively	730	742	O
.	742	743	O

Interestingly	744	757	O
,	757	758	O
significant	759	770	O
associations	771	783	O
were	784	788	O
found	789	794	O
between	795	802	O
CYR61	803	808	B-Gene_or_gene_product
expression	809	819	O
versus	820	826	O
tumor	827	832	B-Pathological_formation
grade	833	838	O
,	838	839	O
pathology	840	849	O
,	849	850	O
gender	851	857	O
,	857	858	O
and	859	862	O
age	863	866	O
at	867	869	O
diagnosis	870	879	O
.	879	880	O

Also	881	885	O
,	885	886	O
a	887	888	O
significant	889	900	O
correlation	901	912	O
existed	913	920	O
between	921	928	O
CTGF	929	933	B-Gene_or_gene_product
mRNA	934	938	O
levels	939	945	O
versus	946	952	O
tumor	953	958	B-Pathological_formation
grade	959	964	O
,	964	965	O
gender	966	972	O
,	972	973	O
and	974	977	O
pathology	978	987	O
.	987	988	O

In	989	991	O
contrast	992	1000	O
to	1001	1003	O
CYR61	1004	1009	B-Gene_or_gene_product
and	1010	1013	O
CTGF	1014	1018	B-Gene_or_gene_product
,	1018	1019	O
no	1020	1022	O
significant	1023	1034	O
association	1035	1046	O
was	1047	1050	O
found	1051	1056	O
between	1057	1064	O
expression	1065	1075	O
of	1076	1078	O
either	1079	1085	O
WISP	1086	1090	B-Gene_or_gene_product
-	1090	1091	I-Gene_or_gene_product
1	1091	1092	I-Gene_or_gene_product
or	1093	1095	O
NOV	1096	1099	B-Gene_or_gene_product
versus	1100	1106	O
any	1107	1110	O
of	1111	1113	O
the	1114	1117	O
pathological	1118	1130	O
features	1131	1139	O
.	1139	1140	O

Furthermore	1141	1152	O
,	1152	1153	O
Cox	1154	1157	O
regression	1158	1168	O
analysis	1169	1177	O
showed	1178	1184	O
that	1185	1189	O
CYR61	1190	1195	B-Gene_or_gene_product
and	1196	1199	O
CTGF	1200	1204	B-Gene_or_gene_product
expression	1205	1215	O
had	1216	1219	O
a	1220	1221	O
significant	1222	1233	O
correlation	1234	1245	O
with	1246	1250	O
patient	1251	1258	B-Organism
survival	1259	1267	O
.	1267	1268	O

These	1269	1274	O
results	1275	1282	O
suggest	1283	1290	O
that	1291	1295	O
CYR61	1296	1301	B-Gene_or_gene_product
and	1302	1305	O
CTGF	1306	1310	B-Gene_or_gene_product
may	1311	1314	O
play	1315	1319	O
a	1320	1321	O
role	1322	1326	O
in	1327	1329	O
the	1330	1333	O
progression	1334	1345	O
of	1346	1348	O
gliomas	1349	1356	B-Pathological_formation
;	1356	1357	O
their	1358	1363	O
levels	1364	1370	O
at	1371	1373	O
diagnosis	1374	1383	O
may	1384	1387	O
have	1388	1392	O
prognostic	1393	1403	O
significance	1404	1416	O
;	1416	1417	O
and	1418	1421	O
these	1422	1427	O
proteins	1428	1436	O
might	1437	1442	O
serve	1443	1448	O
as	1449	1451	O
valuable	1452	1460	O
targets	1461	1468	O
for	1469	1472	O
therapeutic	1473	1484	O
intervention	1485	1497	O
.	1497	1498	O

